Spyre Therapeutics to Participate in Key Investor Conferences in June 2026

WALTHAM, Massachusetts – May 2026 – Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company focused on developing innovative long-acting antibody therapies, has announced its participation in two major healthcare investor conferences scheduled for June 2026. The company aims to strengthen engagement with investors while highlighting recent progress across its clinical development programs focused on inflammatory bowel disease (IBD) and rheumatic diseases.

Major Healthcare Conferences on the June Schedule

According to the company's latest announcement, members of Spyre Therapeutics' executive leadership team will attend and participate in presentations and investor meetings at two highly regarded healthcare investment events.

Jefferies Global Healthcare Conference

The first event on the company's calendar is the Jefferies Global Healthcare Conference, which will take place in New York.

• Date: June 3, 2026
• Location: New York City
• Fireside Chat: 12:15 p.m. Eastern Time

The conference is recognized as one of the healthcare industry's premier investment gatherings, bringing together biotechnology executives, institutional investors, analysts, and healthcare experts from around the world.

Goldman Sachs 47th Annual Global Healthcare Conference

Spyre Therapeutics will also participate in the Goldman Sachs 47th Annual Global Healthcare Conference, another influential event that attracts leading pharmaceutical and biotechnology companies.

• Date: June 8, 2026
• Location: Miami, Florida
• Fireside Chat: 10:00 a.m. Eastern Time

The conference serves as an important platform for public companies to discuss business strategies, pipeline developments, clinical progress, and long-term growth opportunities with members of the investment community.

Management Team to Meet Investors

Beyond the scheduled presentations, members of Spyre Therapeutics' management team will conduct one-on-one meetings with investors throughout both conferences. These meetings provide an opportunity for institutional investors, analysts, and stakeholders to gain deeper insight into the company's strategic direction and clinical programs.

Investor engagement remains a key component of Spyre's corporate strategy as the company advances multiple therapeutic candidates through clinical development.

Webcast Access for Investors

Investors and interested parties who are unable to attend the conferences in person will still have access to company presentations. Spyre Therapeutics confirmed that live audio webcasts and replay recordings will be made available through the company's Investor Relations website.

This approach ensures broader accessibility and transparency for shareholders, analysts, and potential investors seeking updates regarding the company's progress and future plans.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company dedicated to transforming treatment standards for patients suffering from inflammatory bowel disease and rheumatic disorders. The company focuses on developing next-generation biologic therapies using advanced antibody engineering technologies.

Its scientific strategy centers on creating long-acting antibodies and antibody combinations designed to provide enhanced efficacy, improved durability, and potentially better patient outcomes compared with existing treatment options.

Focus on Inflammatory Bowel Disease

Inflammatory bowel disease remains one of the most significant areas of unmet medical need worldwide. Conditions such as ulcerative colitis and Crohn's disease affect millions of patients and often require lifelong treatment.

Spyre's research programs seek to address these challenges by developing therapies that can offer sustained disease control while potentially reducing treatment burdens for patients.

Pipeline Highlights

The company's development pipeline includes several investigational therapies utilizing extended half-life antibody technology. Current research programs target important biological pathways involved in inflammation and immune system regulation, including:

• α4β7 (Alpha-4 Beta-7)
• TL1A
• IL-23

These targets have attracted significant interest within the biotechnology industry because of their potential role in treating inflammatory and autoimmune diseases.

Recent Clinical Progress Supports Investor Interest

Spyre Therapeutics has generated increasing attention within the biotechnology sector following recent updates from its clinical development programs.

Earlier in 2026, the company reported positive topline induction data from Part A of its Phase 2 SKYLINE trial evaluating SPY001 in patients with moderate-to-severe ulcerative colitis. Management stated that the data demonstrated promising efficacy potential along with a safety profile that aligned with expectations for the α4β7 therapeutic class.

These developments have strengthened investor interest in the company's pipeline and may become key discussion topics during the upcoming healthcare conferences.

Why Investor Conferences Matter for Biotechnology Companies

Participation in major healthcare investor conferences plays a critical role in the growth strategy of emerging biotechnology companies. These events provide opportunities to:

• Present clinical and business updates.
• Build relationships with institutional investors.
• Increase market visibility.
• Discuss future development plans.
• Expand analyst coverage.
• Support long-term shareholder value creation.

For companies like Spyre Therapeutics that are actively advancing clinical-stage assets, maintaining strong communication with the investment community is especially important as development milestones continue to drive valuation and strategic opportunities.

Growing Momentum in the Biotechnology Sector

The biotechnology industry continues to experience significant innovation in antibody-based therapeutics. Companies developing novel treatments for chronic inflammatory diseases remain a major focus for investors due to the substantial global market opportunity and ongoing demand for more effective therapies.

Spyre Therapeutics' participation in high-profile healthcare conferences reflects the growing attention surrounding its research platform and clinical programs. As the company advances its portfolio, investors will be closely watching for additional clinical data, regulatory developments, and strategic updates throughout 2026.

Looking Ahead

With several important clinical programs underway and increasing visibility among healthcare investors, Spyre Therapeutics enters the summer conference season with positive momentum. The upcoming presentations at the Jefferies Global Healthcare Conference and the Goldman Sachs Global Healthcare Conference are expected to provide further insight into the company's scientific progress, development strategy, and long-term vision.

As competition within the biotechnology sector intensifies, continued execution across clinical development, investor engagement, and strategic planning will remain essential for Spyre Therapeutics as it works toward advancing innovative therapies for patients with inflammatory bowel disease and rheumatic diseases.

Source: Information compiled from Spyre Therapeutics corporate announcements and investor communications.

#SpyreTherapeutics #Biotechnology #HealthcareInvesting #InvestorConferences #SlimScan #GrowthStocks #CANSLIM